The MDS Beacon™

Seattle Genetics Raises Funds For Research – Seattle Genetics announced that it is increasing its cash by approximately $118.2 million through the issuance of common stock. The funds will be used, among other things, for research and development, including clinical trials. The company has several compounds under development for the treatment of blood cancers. In particular, they are conducting clinical trials for lintuzumab (SGN-33), which has received orphan drug status from the FDA for the treatment of acute myeloid leukemia and myelodysplastic syndromes. For more information, please see the Seattle Genetics press release.

Blood And Stem Cell Transplant Patient/Family Luncheon – The Leukemia & Lymphoma Society (LLS) will be hosting a luncheon for blood and stem cell transplant patients and their caregivers in cooperation with The Nebraska Medical Center on August 20 at 11:30 am in Omaha, NE. The event is free, but registration is requested. For more information, please visit the LLS Web Site.

For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.